Skip to content
A medical professional in a white coat consults a computer and research journal in a medical library

Clinical resources

Start with the research.

Good questions deserve a closer look at the evidence. This library brings together published cannabinoid research for clinicians, researchers and anyone exploring the field.

Browse by topic and follow the links to the original papers. The studies cover different compounds, formulations and settings. They are general literature, not evidence of a benefit from a Promethean BioPharma medicine.

94 topics across 17 letters · 860 linked papers

A

Alzheimer's Disease

A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology. Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.

Antioxidant

Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress. Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure.

Anxiety

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Antidepressant-like and anxiolytic-like effects of Cannabidiol: a chemical compound of Cannabis sativa. Cannabinoid-related Agents in the Treatment of Anxiety.

Autism

Alterations in the endocannabinoid system in the rat valproic acid model of autism. Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling. Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders.
Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders. Deficient Social and Play Behavior in Juvenile and Adult Rats after Neonatal Cortical Lesion: Effects of Chronic Pubertal Cannabinoid Treatment. Endocannabinoid System as Novel Therapeutic Target for Autism Treatment. Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child. Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces.

Autoimmune

An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand? Cannabis Use in Fibromyalgia. Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Endocannabinoids and immune regulation. Endocannabinoids and the Immune System in Health and Disease. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Medical cannabis: A forward vision for the clinician. Medical Cannabis for the Treatment of Fibromyalgia. Safety and Efficacy of Medical Cannabis in Fibromyalgia. Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.

B

Breast Cancer

Antitumor activity of plant cannabinoids with emphasis on the effect of Cannabidiol on Human Breast Carcinoma. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.

C

Cancer

A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy.
Anticancer mechanisms of cannabinoids. Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells. Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Antitumorigenic Effects of Cannabinoids beyond Apoptosis. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Cannabidiol as potential anticancer drug. Cannabidiol (CBD) Priming Enhances Cisplatin Killing Of Cancer Cells. Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. Cannabinoid-associated cell death mechanisms in tumor models. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells. Cannabinoid receptor ligands as potential anticancer agents — high hopes for new therapies? Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Cannabinoid receptors as novel targets for the treatment of melanoma. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non–Small Cell Lung Cancer Growth and Metastasis. Cannabinoids and Cancer. Cannabinoids and ceramide: Two lipids acting hand-by-hand. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Cannabinoids, endocannabinoids, and cancer. Cannabinoids for Cancer Treatment: Progress and Promise. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes. Cannabinoids: potential antitumoral agents? Cannabis and Cannabinoids. Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with a Philadelphia Chromosome Mutation. Cannabis in cancer care. Cannabidiol inhibits angiogenesis by multiple mechanisms. Ceramide: A new second messenger of cannabinoid action. Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions. COX-2 and PPAR-γ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells. Differential role of cannabinoids in the pathogenesis of skin cancer. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Endocannabinoids as Guardians of Metastasis. Endocannabinoids in endocrine and related tumours. Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedules. Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa. Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Id-1 is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target. Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism. Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1. Inhibition of tumor angiogenesis by cannabinoids. Integrating cannabis into clinical cancer care. In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Involvement of PPARc in the antitumoral action of cannabinoids on hepatocellular carcinoma. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers. Medical marijuana for cancer. Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Potentiation of cannabinoid-induced cytotoxicity in Mantle Cell Lymphoma through modulation of ceramide metabolism. Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid. Proapoptotic effect of endocannabinoids in prostate cancer cells. Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. Receptor-dependent and Receptor-independent Endocannabinoid Signaling: A Therapeutic Target for Regulation of Cancer Growth. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. The antitumor activity of plant-derived non-psychoactive cannabinoids. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. The endocannabinoid system and cancer: therapeutic implication. The endocannabinoid system in cancer. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. The Expression Level of CB1 and CB2 Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas. The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. The use of cannabinoids as anticancer agents. Towards the use of cannabinoids as antitumour agents. United States patent application publication for phytocannabinoids in the treatment of cancer. Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.

Cannabidiol

Action of cannabidiol on the anxiety and other effects produced by Δ-9THC in normal subjects. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabidiol: An Overview of Some Pharmacological Aspects.

Cardiovascular

CB1 - Receptor

Allosteric modulation of the cannabinoid CB1 receptor. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of Sceletium tortuosum L.

CB2 - Receptor

Activation of cannabinoid receptor type II by AM1241 protects adipose-derived mesenchymal stem cells from oxidative damage and enhances their therapeutic efficacy in myocardial infarction mice via Stat3 activation. Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. CB2 cannabinoid receptors as an emerging target for demyelinating diseases.

Colon Cancer

The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.

D

Diabetes

Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Cannabinoids Regulate Bcl-2 and Cyclin D2 Expression in Pancreatic β Cells.

E

Endocannabinoid System

Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Anandamide and 2-arachidonoylglycerol: Pharmacological Properties, Functional Features, and Emerging Specificities of the Two Major Endocannabinoids.
Antiangiogenic Activity of the Endocannabinoid Anandamide: Correlation to its Tumor Suppressor Efficacy. An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Cannabinoid pharmacology: the first 66 years. Cannabinoid receptors and endocannabinoids: Evidence for new players. Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. Cannabinoid system and cyclooxygenases inhibitors. Cannabinoid receptors and their ligands. Cannabis, a complex plant: different compounds and different effects on individuals. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to Δ9-Tetrahydrocannabinol. Endocannabinoid Signaling Regulates Sleep Stability. Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown. Endocannabinoid CB1 receptor-mediated rises in Ca2+ and depolarization-induced suppression of inhibition within the laterodorsal tegmental nucleus. Endocannabinoids and the haematological system. Endocannabinoid signalling and the deteriorating brain. Endocannabinoid System in First Trimester Placenta: Low FAAH and High CB1 Expression Characterize Spontaneous Miscarriage. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Enhanced discriminative stimulus effects of Δ9-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys. Estrogen Receptor Beta and 2-arachidonoylglycerol Mediate the Suppressive Effects of Estradiol on Frequency of Postsynaptic Currents in Gonadotropin-Releasing Hormone Neurons of Metestrous Mice: An Acute Slice Electrophysiological Study. Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system? Modulating the endocannabinoid system in human health and disease - successes and failures. Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity. Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ9-Tetrahydrocannibinol, Cannabidiol and Cannabinol. Recent advances in cannabinoid receptor agonists and antagonists. Relationships between eicosanoids and cannabinoids. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation Role and Function of Endocannabinoid System in Major Depressive Disease. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease. The endocannabinoid system and migraine. The Endocannabinoid System: A New Target for the Regulation of Energy Balance and Metabolism The Endocannabinoid System as an Emerging Target of Pharmacotherapy. The Endocannabinoid System, Cannabinoids, and Pain. The endocannabinoid system drives neural progenitor proliferation. The endocannabinoid system in normal and pathological brain ageing. The endogenous cannabinoid system and its role in nociceptive behavior. The orphan receptor GPR55 is a novel cannabinoid receptor. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. The therapeutic potential of novel cannabinoid receptors.

G

Gastrointestinal Disease

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis.
Cannabinoids and the gastrointestinal tract. Cannabis Alleviates Symptoms of Crohn’s Disease. Cannabis Finds Its Way into Treatment of Crohn's Disease. Cannabis Induces a Clinical Response in Patients with Crohn's Disease: A Prospective Placebo-Controlled Study. Cannabis use amongst patients with inflammatory bowel disease. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease. Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation andin vitromotility disturbances in rat colitis. Treatment of Crohn's disease with cannabis: an observational study.

General

Acute Pulmonary Physiologic Effects of Smoked Marijuana and Oral Δ9-Tetrahydrocannabinol in Healthy Young Men. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Cannabinoids in health and disease.
Cannabis and Eicosanoids: A Review of Molecular Pharmacology. Cannabis sativa: The Plant of the Thousand and One Molecules. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Early phytocannabinoid chemistry to endocannabinoids and beyond. Future of Cannabis and Cannabinoids in Therapeutics. Medical Marijuana: Clearing Away the Smoke. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Phytocannabinoids beyond the Cannabis plant - do they exist? Plant cannabinoids: a neglected pharmacological treasure trove. Review on clinical studies with cannabis and cannabinoids 2010-2014. Therapeutic benefits of cannabis: a patient survey. Therapeutic aspects of cannabis and cannabinoids. Therapeutic potential of cannabis-related drugs. Toward drugs derived from cannabis.

Glioma

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.

I

Immune Function

Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties.

Inflammation

Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study Cannabinoid-based drugs as anti-inflammatory therapeutics Cannabinoid CB2 receptors in human brain inflammation Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases? Cannabinoids as novel anti-inflammatory drugs Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation Cannabinoids, inflammation, and fibrosis Cannabinoids in models of chronic inflammatory conditions Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells Cannabinomimetic Control of Mast Cell Mediator Release: New Perspective in Chronic Inflammation Clinical Implications for Cannabinoid Use in the Rheumatic Diseases Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders

Ischemia

Activation of Cannabinoid CB2 ReceptoreMediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion Cannabidiol administration after hypoxiaeischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia HU-211, a Novel Noncompetitive N-Methyl-d-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat Mechanisms of cannabidiol neuroprotection in hypoxiceischemic newborn pigs: Role of 5HT1A and CB2 receptors The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke Update on the Role of Cannabinoid Receptors after Ischemic Stroke

L

Lung Cancer

Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1 Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1 Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis

M

Memory

Mental Illness

Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Cannabidiol as a potential treatment for psychosis Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Cannabidiol for the treatment of psychosis in Parkinson's disease Cannabidiol, neuroprotection and neuropsychiatric disorders Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential Cortical GAD67 deficiency results in lower cannabinoid 1 receptor mRNA expression: Implications for schizophrenia Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants Motor effects of delta 9 THC in cerebellar Lurcher mutant mice Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: additional evidence The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms The development of cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms. Therapeutical use of the cannabinoids in psychiatry Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice Cannabis as a substitute for alcohol and other drugs CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence The endocannabinoid system and emotional processing: A pharmacological fMRI study with Δ9-tetrahydrocannabinol

Migraine

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions? Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

MTHFR Gene Mutation

Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure

Multiple Sclerosis

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system?
Cannabinoid Modulation of Neuroinflammatory Disorders Cannabinoids and multiple sclerosis Cannabinoids control spasticity and tremor in a multiple sclerosis model Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up Cannabinoids in the management of spasticity associated with multiple sclerosis Clinical experiences with cannabinoids in spasticity management in multiple sclerosis Effects of cannabis on cognitive function in patients with multiple sclerosis Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study Randomized, controlled trial of cannabisbased medicine in central pain in multiple sclerosis Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms The effect of cannabis on tremor in patients with multiple sclerosis The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

N

Neuro-protective and Neuro-generative

Activation of Type 1 Cannabinoid Receptor (CB1R) Promotes Neurogenesis in Murine Subventricular Zone Cell Cultures Cannabidiol administration after hypoxiaeischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Cannabidiol and (-)D9-tetrahydrocannabinol are neuroprotective antioxidants Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice Cannabidiol, neuroprotection and neuropsychiatric disorders Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis Cannabinoids and neuroprotection in basal ganglia disorders Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity Endocannabinoids and traumatic brain injury Endocannabinoids in the Retina: From Marijuana to Neuroprotection Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection Molecular Mechanisms of Cannabinoid Protection from Neuronal Excitotoxicity Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes Neuroprotective antioxidants from marijuana Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist Prospects for cannabinoid therapies in basal ganglia disorders Protective effects of Δ9-tetrahydrocannabinol against N-methyl-D-aspartate-induced AF5 cell death The Cannabinoid WIN55212-2 Promotes Neural Repair After Neonatal Hypoxia–Ischemia The CB₁ cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines The endocannabinoid system as a target for the treatment of neurodegenerative disease The endocannabinoid system in normal and pathological brain ageing The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects

P

Pain

An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease Medicinal cannabis in the treatment of chronic pain Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: an updated review
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint Cannabinoid–Opioid Interaction in Chronic Pain Cannabinoid receptors and pain Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain Cannabinoids for Neuropathic Pain Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials Cannabinoids in the management of difficult to treat pain Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS) Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Combined treatment with morphine and Δ9 -tetrahydrocannibinol (THC) in rhesus monkeys: antinociceptive tolerance and withdrawal Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol Prescribing cannabis for harm reduction Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes Role of Cannabinoids in Pain Management Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ9-tetrahydrocannabinol in the rat Smoked cannabis for chronic neuropathic pain: a randomized controlled trial Stable dose cannabinoid medicine (Sativex®, THC+CBD) can provide sustained efficacy in the treatment of refractory painful diabetic neuropathy or other peripheral neuropathic pain associated with allodynia. Survey Results of Pain Treatments in Adults with Cerebral Palsy Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine Targeting CB2 receptors and the endocannabinoid system for the treatment of pain The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects The Endocannabinoid System, Cannabinoids, and Pain The endogenous cannabinoid system and its role in nociceptive behavior The Pharmacologic and Clinical Effects of Medical Cannabis Therapeutic Benefits of Cannabis: A Patient Survey Use of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use δ-Ctenitoxin-Pn1a, a Peptide from Phoneutria nigriventer Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats

Parkinson's Disease

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series Cannabidiol for the treatment of psychosis in Parkinson’s disease Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

Pregnancy

A Longitudinal Study of Prenatal Marijuana Use Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines Cannabis and Breastfeeding
Endocannabinoid System in First Trimester Placenta: Low FAAH and High CB1 Expression Characterize Spontaneous Miscarriage Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling Five-year follow-up of rural Jamaican children whose mothers used marijuana during pregnancy Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco Exposure on Neonatal Growth Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation Maternal Marijuana Use During Lactation and Infant Development at One Year Multiple Roles for the Endocannabinoid System During the Earliest Stages of Life: Pre- and Postnatal Development Prenatal Marijuana Exposure and Neonatal Outcomes in Jamaica: An Ethnographic Study The Endocannabinoid-CB Receptor System: Importance for development and in pediatric disease Transfer of Inhaled Cannabis Into Human Breast Milk

Prostate Cancer

Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest Cannabinoid receptor as a novel target for the treatment of prostate cancer Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines

Psychedelic Therapy

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. A potential role for psilocybin in the treatment of obsessive-compulsive disorder. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.
Beckley Foundation for research into cannabis & psychedelics. Classical psychedelics for the treatment of depression and anxiety: A systematic review. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychedelics and Psychedelic-Assisted Psychotherapy. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights from Psychedelic Medicine and Animal Models. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Spontaneous and deliberate creative cognition during and after psilocybin exposure. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Trial of Psilocybin versus Escitalopram for Depression.

Pulmonary Function

Association Between Marijuana Exposure and Pulmonary Function Over 20 Years Bronchodilator Effect Of Delta1-Tetrahydrocannabinol Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety

S

Safety

Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS) CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study Endocannabinoid signaling in neurotoxicity and neuroprotection Molecular Mechanisms of Cannabinoid Protection from Neuronal Excitotoxicity Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes Neuroprotective Effect of(−)Δ9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on b-amyloid-induced toxicity in PC12 cells Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism Protective effect of cannabidiol against cadmium hepatotoxicity in rats Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent Safety and Toxicology of Cannabinoids

Skeletal System

Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes Cannabinoid receptors and the regulation of bone mass

Sleep

Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats A Longitudinal Study of Prenatal Marijuana Use A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats
Around‐the‐Clock Oral THC Effects on Sleep in Male Chronic Daily Cannabis Smokers Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis Cannabidiol in Anxiety and Sleep: A Large Case Series (−)δ9 THC as an hypnotic Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana Endocannabinoid Signaling Regulates Sleep Stability Functional Role for Cannabinoids in Respiratory Stability During Sleep Intrahippocampal administration of anandamide increases REM sleep Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat Modulation of Sleep-Wake Cycles in Mice and Rats with Cannabinoids Potential Effects of Cannabidiol as a Wake-Promoting Agent Proof of concept trial of dronabinol in obstructive sleep apnea The effects of cannabinoid administration on sleep: a systematic review of human studies The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent

Spasticity

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Cannabinoids in the management of spasticity associated with multiple sclerosis

Sports

Activation of Cannabinoid CB2 Receptor–Mediated AMPK/CREB Pathway Reduces Cerebral Ischemic Injury Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it’s role in metabolic defects and neuronal apoptosis after TBI
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury Cannabidiol­ treated rats exhibited higher motor score after cryogenic spinal cord injury. Cannabinoid agonist rescues learning and memory after a traumatic brain injury Cannabinoid CB2 Receptor Activation Attenuates Motor and Autonomic Function Deficits in a Mouse Model of Spinal Cord Injury Cannabinoids and the skeleton: From marijuana to reversal of bone loss Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia Endocannabinoids and traumatic brain injury Estradiol Decreases Cortical Reactive Astrogliosis after Brain Injury by a Mechanism Involving Cannabinoid Receptors HU­211, a Novel Noncompetitive N­Methyl­D­Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players* Mechanisms of cannabidiol neuroprotection in hypoxiceischemic newborn pigs: Role of 5HT1A and CB2 receptors Peripheral cannabinoid receptor, CB2, regulates bone mass Tissue Engineering of Cartilage; Can Cannabinoids Help? Role of cannabinoids in the regulation of bone remodeling The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke The Role of Type 2 Cannabinoid Receptor in Bone Metabolism Update on the Role of Cannabinoid Receptors after Ischemic Stroke

See how the tablet is made.

Explore manufacturing About TCann